Eli Lilly’s Cyramza to Become the Leader of the Overall Market – Although Roche’s Herceptin has been the best-selling brand in Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) because of its status as a first-line standard of care, its growth over the forecast period will be limited by the small population of HER2-positive patients within the G/GEJAC market, as well as the launch of trastuzumab biosimilars. Eli Lilly’s anti-angiogenesis drug Cyramza, aims to expand its drug label to include first-line treatment for patients with HER2-negative, advanced G/GEJAC, which is a segment with huge unmet need. If Cyramza manages to show considerable clinical benefits in these first-line patients, GlobalData anticipates that it will be approved in 2018; upon its launch, Cyramza will become the first targeted therapy to enter this market segment, which has thus far only been occupied by generic chemotherapies. With a treatment duration that is expected to be longer in the first line of therapy, the uptake of Cyramza in this setting will further enhance the sales potential of this drug.
The figure below presents the gap analysis for the forecast period of companies in the G/GEJAC space.
GlobalData’s PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma – Global Drug Forecast and Market Analysis to 2024 report provides analysis of the global switchgear market, with annualized market data from 2006 and forecast to 2020, with a particular focus on the US, Canada, China, India, the UK, Italy and Saudi Arabia.
Single user price: $10,995